June 19, 2014

Actavis confirmed that the U.S. District Court for the District of Delaware found certain claims of U.S. Patent Nos. 6,335,031 and 6,316,023 valid and infringed by the company's rivastigmine transdermal system, a generic version of Exelon Patch from Novartis.

March 12, 2013

Actavis is challenging Novartis' patent on a patch used to treat Alzheimer's disease, Actavis said.

September 22, 2011

Dr. Reddy's Labs has launched a drug for treating Alzheimer's disease, the company said.

June 30, 2010

Watson Pharmaceuticals has launched a generic version of a drug used to treat dementia under...